[ad_1]
Original title: China’s four new corona vaccines have entered phase III clinical trials and production capacity is expected to reach more than 1 billion doses next year.
Science and Technology Journal reporter Liu Yin Cao Xiuying
“At present, China’s corona new vaccine research and development work is generally in a leading position. Each technical path has vaccines that have entered the clinical research stage. There have been 11 vaccines in trials. clinical trials, of which 4 vaccines have entered phase III clinical trials. “
On September 25, at a briefing on the progress of the work of the new corona virus vaccine held by the State Information Office, Wu Yuanbin, director of the Department of Social Development and Technology of the Ministry of Science and Technology , took the initiative to bring good news. He said that of the 4 vaccines that have entered phase III clinical trials, 3 are inactivated vaccines and 1 is an adenovirus vector vaccine. Recombinant protein vaccines, nucleic acid vaccines, and attenuated influenza virus vector vaccines are undergoing phase Ⅰ and phase Ⅱ clinical trials.
How long will the vaccine be on the market?
Wu Yuanbin presented that the four vaccines that have entered phase III clinical trials are progressing smoothly. Chinese vaccine companies have signed cooperative agreements with institutions in many countries to jointly implement phase III clinical trials on the basis of compliance with laws and regulations.
Specifically, the two inactivated vaccines from Zhongsheng Company have conducted phase III clinical trials in the Middle East, and more than 35,000 people have been inoculated. Vaccine safety is currently observed to be good and no serious adverse reactions have occurred. The vaccine was carried out in relevant countries of South America and Southeast Asia, and phase III clinical trials were carried out in accordance with the law, and vaccination was carried out in an orderly manner; The adenovirus vector vaccine jointly developed by the Military Medical Research Institute and Cansino was approved for phase III clinical trials in relevant countries in Europe and Asia. It has started to join the group.
Specific progress in vaccine research and development affects people’s hearts. Yang Sheng, head of the Department of Drug Registration Management of the State Administration of Medicines, emphasized that the new coronavirus vaccine is used to prevent new coronavirus infections in healthy people, and its safety and effectiveness must meet relevant standards. .
“Pre-clinical studies, phase I and phase II clinical studies must be completed prior to marketing, and the corresponding protective effects must be demonstrated through phase III clinical trials to demonstrate that the safety and efficacy of the vaccine meet established standards. “explained Yang Sheng. It is necessary to complete verification of the commercial scale production process, establish controllable quality standards and demonstrate that the proposed vaccine has acceptable safety, clear efficacy and quality control capability.
What is the impact of the new coronavirus mutation on vaccine development? Zhang Xinmin, head of the professional organization for the management of emergency vaccine research and development projects and director of the Biological Center of the Ministry of Science and Technology, said that there have been three academic consensuses: first, so far, the mutation of the new corona virus is not big; second, the new corona virus has not mutated It will have a substantial impact on the development of the vaccine; third, the immune response induced by the developing vaccine can effectively neutralize the new mutated coronavirus.
What is the offer and the price?
In response to public concern about the supply and distribution of the new corona vaccine, Zheng Zhongwei, leader of the vaccine research and development team of the research team and director of the Center for Technology and Medical Science Development of the National Commission of Salud y Salud revealed that it will be based on high-risk groups, high-risk groups and the general population. Groups are stratified to comply with vaccination. It is estimated that by the end of 2020, the annual production capacity of China’s new corona vaccine will reach 610 million doses, reaching more than 1 billion doses next year (2021).
Regarding the issue of price of public concern, Zheng Zhongwei emphasized that the price of the new corona vaccine in China should be within the acceptable range for the public. “In the emergency use phase, we have a unified guide price. After the official launch of the vaccine, the price of the vaccine can be adjusted according to different technical routes, scale of use and other factors,” he said, but not matter what The accessibility and affordability of the new corona vaccine should be achieved, and the guide price of the new corona vaccine should be within the range acceptable to the public.
Will the vaccine be effective for a long time?
Zeng Guang, chief epidemiologist at the Chinese Center for Disease Control and Prevention, admitted that it took humans only 9 months to discover the new coronavirus. How long is the protection period of each vaccine after vaccination? A lot of long-term research work is needed.
“Currently, the most positive result is that the results of the control of the serum of the subjects who were vaccinated for the first time in China show that the antibodies are still at a high level, which suggests that the vaccine may have a protective effect against longer term, “Zeng Guang said, but replied to a certain paragraph. The exact protection of the new coronavirus vaccine can only be achieved after completing the phase III clinical trial.
“Until now, no R&D unit in the world has completed all phase III clinical trials. China is in the first tier of phase III clinical trials, but we must also be patient,” said Zeng Guang.
Can I remove my mask after vaccination?
“Do I have to keep wearing a mask after vaccination?”
When asked by reporters, Zeng Guang replied that it should be safe for the vaccinated to remove the mask four weeks after completing the new corona vaccination procedure.
“However, the respiratory infectious diseases that he will face this winter and next spring include influenza, streptococcus pneumoniae, adenovirus and other infectious diseases in addition to the new corona, and no new corona vaccine can be 100% effective.” More importantly, Zeng Guang stressed that most people may not be vaccinated this winter and next spring. Therefore, it is still necessary to decide whether to wear a mask based on the domestic new corona epidemic and other respiratory infectious diseases, the place of gathering, whether the ventilation measures are good, and the autoimmune status.
“Especially some elderly people, chronic disease patients and children should strengthen protection. It is better to be cautious. We should also maintain the good habits of wearing masks, washing hands frequently and keeping distance,” Zeng Guang emphasized.
